welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Dual Focus NBI and pCLE in FAP Related Duodenal AdenomaBackground: Familial adenomatous pol...
-
Celebrex Reduces Polyps Density in Familial Adenomatous Polyposis (FAP)This week in the Orphanet Journal of Rar...
-
Inherited Colorectal Cancer Syndromes – Diagnosis and ManagemntColorectal cancer is the most common gas...
-
Levels of Rectal Mucosal Polyamines and Prostaglandin E2 Predict Ability of DFMO and Sulindac to Prevent Colorectal ...BACKGROUND & AIMS : Combination of p...
-
Familial Adenomatous Polyposis. Laparoscopic Total Proctocolectomy with J-Pouch Ileoanal Anastomosishttps://www.youtube.com/watch?v=4l1qS1wa...
-
Thirty Years of the Ileal-Anal Pouch and BeyondStill referred to as a new surgical proc...
-
Nexavar Narrative: 7 Month Updatehttps://www.youtube.com/watch?v=4I3D66vr...